SCHEMBL6922463

SCHEMBL6922463

CCOC(=O)C(CC(C)C)P(=O)(OCC)OCC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.40
POLB P06746 2/20 0.37
ALDH1A1 P00352 3/20 0.36
TSHR P16473 3/20 0.36
CYP3A4 P08684 2/20 0.36
CYP2C9 P11712 2/20 0.36
CYP2C19 P33261 2/20 0.36
HSD17B10 Q99714 1/20 0.34
MAPT P10636 1/20 0.33
ADAM17 P78536 2/20 0.33
MMP1 P03956 1/20 0.33
MMP3 P08254 1/20 0.33
MMP9 P14780 1/20 0.33
TAS1R3 Q7RTX0 1/20 0.33
TAS1R1 Q7RTX1 1/20 0.33
CYP2D6 P10635 1/20 0.33
ALOX15 P16050 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8532180 0.90 POLB (0.40) GAAPOLBALDH1A1TSHRCYP3A4
SCHEMBL9651262 0.87 GAA (0.42) GAAPOLBALDH1A1CYP3A4CYP2C9
SCHEMBL10788776 0.85 POLB (0.37) GAAPOLBALDH1A1TSHRCYP3A4
SCHEMBL30942674 0.84 POLB (0.36) GAAPOLBALDH1A1TSHRCYP3A4
SCHEMBL7617677 0.83 GAA (0.41) GAAPOLBTSHRCYP3A4CYP2C9
SCHEMBL4807731 0.83 GAA (0.39) GAAPOLBALDH1A1CYP3A4CYP2C9
SCHEMBL1052265 0.82 POLB (0.40) GAAPOLBALDH1A1TSHRCYP3A4
SCHEMBL14524858 0.79 POLB (0.38) GAAPOLBALDH1A1TSHRCYP3A4
SCHEMBL1051880 0.79 POLB (0.53) GAAPOLBALDH1A1TSHRCYP3A4
SCHEMBL11318843 0.79 ALDH1A1 (0.37) GAAPOLBALDH1A1TSHRCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4638458-A1 MALT1 INHIBITORS Janssen Pharmaceutica NV (BE) 2025-10-29 EP disclosed
WO-2024133859-A1 MALT1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2024-06-27 WO disclosed
US-20230321123-A1 INHIBITORS OF PSEUDOMONAS AERUGINOSA VIRULENCE FACTOR LasB HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH (DE) 2023-10-12 US disclosed
US-20230321123-A1 INHIBITORS OF PSEUDOMONAS AERUGINOSA VIRULENCE FACTOR LasB HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH (DE) 2023-10-12 US disclosed
US-6518260-B1 (α-aminophosphino) peptide derivatives, method for making same and therapeutic applications thereof INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2003-02-11 US disclosed
EP-0309766-B1 N-acylamino acid derivatives and their use BANYU PHARMA CO LTD (JP) 1998-04-15 EP disclosed
US-5506356-A RENIN INHIBITORS; HYPOTENSIVE AGENTS BANYU PHARMACEUTICAL CO., LTD. (JP) 1996-04-09 US disclosed
US-5481036-A RENIN INHIBITORS, HYPOTENSIVE AGENTS BANYU PHARMACEUTICAL CO., LTD. (JP) 1996-01-02 US disclosed
US-5319082-A N-acylamino acid derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 1994-06-07 US disclosed
US-5240924-A Dipeptide hypotensives BANYU PHARMACEUTICAL CO., LTD. (JP) 1993-08-31 US disclosed
US-5122523-A Hypotensive agents BANYU PHARMACEUTICAL CO., LTD. (JP) 1992-06-16 US disclosed
EP-0309766-A2 N-acylamino acid derivatives and their use BANYU PHARMACEUTICAL CO., LTD. (JP) 1989-04-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230321123-A1 INHIBITORS OF PSEUDOMONAS AERUGINOSA VIRULENCE FACTOR LasB SERPINB1, LTA, TFPI GAA 743/4885POLB 470/4885ALDH1A1 2662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.